V158866 / Neuritek Therap, Ligand - LARVOL DELTA

Announcement of results for the year ended 31 December 2012 (Vernalis) - "Announced today, patients being recruited into a Phase II POC study (April 2013)"

Enrollment open • Pain

Ligand provides a corporate update and announces May 6th as the date for first quarter earnings call (Businesswire) - "Ligand recently entered into an exclusive worldwide license agreement with Neuritek Therapeutics to develop and commercialize V158866, a novel, oral, selective fatty acid amide hydrolase (FAAH) inhibitor that was discovered using the Vernalis Design Platform (VDP). Neuritek plans to develop V158866 for post-traumatic stress disorder and other CNS diseases."

Licensing / partnership